Citations

Clear

15427 citation(s) found for "Su, Michael".

The Effect of Obesity on the α-Cell Response to Hyperglycemia in the Presence of Amino Acids
Man, Chiara Dalla , Vella, Adrian , Egan, Aoife M. , Mohan, Sneha , Christie, Hannah E. , Boscolo, Francesca S. , Mohan, Sneha , Boscolo, Federica , Christie, Hannah E , Egan, A M , Jensen, Michael , Nair, K Sree, Dalla Man, Chiara , Vella, Adrian , Bailey, Kent R. , Jensen, Michael D. , Nair, K. Sree

Mayo Clinic

Diabetes | September 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2337/db26-0502 | PMID 42726473 Get It

Hyperglycemia in prediabetes is accompanied by increased amino acid (AA) concentrations and impaired suppression of glucagon secretion by glucose. It is unknown whether an abnormal response to AA contributes or hepatic steatosis exacerbates α-cell dysfunction. Therefore, lean participants and participants with obesity (with and without hepatic steatosis) were studied on two occasions in random order using a graded glucose infusion. Saline or an AA mixture was infused. The glucagon secretion rate (GSR) was derived from peripheral glucagon concentrations, and the change in glucose required to reduce GSR by 50% (G50) was calculated for each participant. AAs were measured during the experiment. On both occasions, experimental conditions produced a progressive rise in insulin secretion and an inverse exponential suppression of glucagon. G50 did not differ between groups in response to glucose alone. AA infusion did not change G50 in lean participants. G50 increased during AA infusion in participants with obesity with and without hepatic steatosis, leading us to report these participants as a single group. The relative change in AA concentrations across study days was generally similar between groups. We conclude that despite a normal response to glucose, obesity increases α-cell responses to AA in humans. Article Highlights The aim of this study was to understand the pathogenesis of α-cell dysfunction in prediabetes. The primary hypothesis was that α-cell responsivity to glucose (reduction of the glucagon secretion rate by 50%) is impaired by amino acid (AA) infusion. A secondary hypothesis was that this abnormal response is exacerbated by hepatic steatosis. AA infusion impaired α-cell suppression in response to rising glucose in participants with obesity, but not in lean participants, despite a normal response to glucose alone. This abnormal response was unaffected by the presence or absence of hepatic steatosis. It seems likely that an abnormal α-cell response to AAs precedes an abnormal response to glucose alone.
Prediction of Rhinologic Surgery Within 90 Days Using Item‐Level SNOT‐22 Responses: A Multisite Machine Learning Study of 35,170 Patients
Sramek, Michael , Kumar, Nitish , Patel, Shrinath, Miglani, Amar , Marino, Michael, Lal, Devyani , Kumar, Nitish , Lal, Devyani , Marino, Michael J.

Mayo Clinic

International Forum of Allergy & Rhinology | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/alr.70273 | PMID 42722008 Get It

ABSTRACT Background Optimizing access to cost‐effective care in capacity‐constrained health systems is a contemporary imperative. We evaluated whether machine learning (ML) models using patient‐reported data could optimize access for patients requiring surgical care in rhinology clinics, without need for CT imaging. The outcome was defined as any rhinologic surgery within 90 days of initial evaluation. Methods A de‐identified electronic dataset from patients seen at five distinct sites within an integrated healthcare system between 2018 and 2025 was used to train models. Demographic data and 22‐item Sinonasal Outcome Test (SNOT‐22) responses were studied. Models were trained using stratified 5‐fold cross‐validation with an 80% development cohort and validated in a 20% held‐out validation cohort. Hyperparameters were optimized with Optuna. The primary outcome was performance of any rhinologic surgical intervention within 90 days of initial SNOT‐22. Results Data from 35,170 patients were evaluated. Item‐level responses outperformed use of total SNOT‐22 score in the models. Among models, XGBoost demonstrated best discrimination with AUC of 0.70 (95% CI, 0.69–0.71), outperforming logistic regression (0.66), random forest (0.63), and TabNet (0.66) (all p < 0.001). At optimal threshold, XGBoost achieved 66% sensitivity, 64% specificity, 28% PPV, and 90% NPV. Top predictors for surgery were age, nasal blockage, facial pain or pressure, and decreased sense of smell or taste. Validation on the held‐out cohort remained stable (AUC 0.70), with strong discrimination across sites despite surgical rates ranging from 11.5% to 27.4%. Conclusions Demographics and item‐level SNOT‐22 responses were successful in developing an ML model that demonstrated moderate discrimination and high NPV (90%) for performance of surgery within next 90 days. ML models balanced with human oversight may accelerate triage and optimize surgical yield for rhinology clinics.
Six-Month Indication-Specific Outcomes After Sleeve Gastrectomy to Roux-en-Y Gastric Bypass Conversion: A Nationwide Analysis of the MBSAQIP Database
Urbina, Jorge , Kachmar, Michael, DuCoin, Christopher, Kondapalli, Lalith, Docimo, Salvatore , Clapp, Benjamin, Clapp, Benjamin

Mayo Clinic

No container title available | September 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10655511/v1 Get It

Abstract Introduction Conversion of sleeve gastrectomy (SG) to Roux-en-Y gastric bypass (RYGB) is performed for gastroesophageal reflux disease (GERD), recurrent weight gain, and suboptimal clinical response. We compared early safety, weight loss, and healthcare utilization across indications. Methods We retrospectively analyzed adults undergoing SG-to-RYGB conversion in the 2023 MBSAQIP Participant Use File linked to the Long-Term Follow-Up file. Patients were grouped by indication as GERD, recurrent weight gain, suboptimal clinical response, or other. Baseline, operative, 30-day, and 6-month outcomes were compared using unadjusted analyses. Results Among 12,350 patients, indications were GERD in 59.2%, recurrent weight gain in 24.7%, suboptimal clinical response in 10.5%, and other in 5.6%. Patients with weight-related indications had higher baseline BMI. Major 30-day complications were uncommon and did not differ significantly across groups. Among 8,797 patients with 6-month weight data, mean percent total weight loss (%TWL) was 14.2% for recurrent weight gain, 13.3% for suboptimal clinical response, and 12.7% for both GERD and other indications (P < 0.001). The maximum absolute difference was 1.5 percentage points. Six-month intervention rates were 6.4% for GERD and 6.8% for other indications, compared with 4.2% for recurrent weight gain and 2.8% for suboptimal clinical response (P < 0.001); mortality remained uncommon. Conclusion SG-to-RYGB conversion was associated with low short-term complication rates across indications. Six-month weight loss and healthcare utilization differed in unadjusted comparisons, but weight-loss differences were modest and may reflect baseline case-mix differences.
Patient Characteristics and Outcomes of Acute Pancreatitis Managed in a Hospital-at-Home Program: A Multicenter Retrospective Descriptive Study
Gavrancic, Tatjana , Dumic, Igor , Laenger, Jessica , Jackson, B., Tshabalala, Khanyisile N., Lewis, Michele D. , Paulson, Margaret R. , Maniaci, Michael J. , Bosch, Wendelyn , Jackson, Brittany S, Dumic, Igor , Maniaci, Michael J , Paulson, Margaret R , Lewis, Michele D , Laenger, Jessica

Mayo Clinic

Healthcare | September 9, 2026 | Volume: 14 | Issue: 18 | Pages: 2919

10.3390/healthcare14182919 | PMID 42793458 Get It

Background/Objectives: Hospital-at-home (HaH) programs have emerged as an alternative model to brick-and-mortar (BaM) hospital management of acute conditions such as heart failure, pneumonia, pyelonephritis, and chronic obstructive pulmonary disease exacerbation among the others. However, the clinical management of acute pancreatitis in the HaH setting has never been described in the literature. The primary objective of this study was to describe the demographic and clinical characteristics of patients with acute pancreatitis managed in a Mayo Clinic Advanced Care at home (ACH) program. The secondary objective was to describe feasibility and short-term clinical outcomes. Methods: This multistate, multicenter, retrospective descriptive study included 40 unique patients with acute pancreatitis managed at ACH between 13 October 2020 and 1 June 2024. Repeat admissions were excluded from the primary analysis. Results: The most common etiologies were idiopathic (42.5%), gallstone-related (22.5%), and alcohol-related (12.5%). Peripancreatic fluid collections occurred in 17.5%, necrotizing pancreatitis in 10.0%, pleural effusion in 12.5%, and infected pancreatitis in 7.5%. Intravenous antiemetics were administered to 22.5%, intravenous fluids to 62.5%, and intravenous opioids to 7.5%. Median total hospital length of stay was 5.0 days (IQR, 3.0–8.25), including a median of 3.0 days (IQR, 2.0–4.0) in ACH. Four patients (10.0%; exact 95% CI, 2.8–23.7%) were transferred from ACH to BaM care. Seven-day and 30-day readmission rates were 10% (95% CI: 2.8%, 23.7%) and 5% (95%CI: 0.6%, 16.9%), respectively. The 30-day emergency department visit was 0%. Although 30-day mortality was 2.5% (95% CI: 0.0%, 13.2%), in-program mortality was 0%. Conclusions: Among a highly selected group of clinically stable patients meeting the program’s eligibility criteria, management of acute pancreatitis in ACH was feasible and was associated with low observed rates of unplanned escalations and short-term adverse outcomes.
A Novel De Novo STAG1 Variant at the RAD21 Binding Interface Is Associated With Hypoglycemia, Recurrent Fever, Immunodeficiency and Features of Classical Cohesinopathies
Hussain, Hafiz Muhammad Jafar , Zimmermann, Michael T. , Farris, Joseph , Panwar, Deepak , Thurman, Sarah , Muthusamy, Karthik , Wick, Myra , Klee, Eric W. , Zimmermann, Michael T , Safgren, Stephanie L , Farris, Joseph D , Panwar, Deepak , Thurman, Sarah Allen , Muthusamy, Karthik , Urrutia, Raul , Vairo, Filippo , Klee, Eric W , Safgren, Stephanie L. , Urrutia, Raúl , Vairo, Filippo Pinto e

Mayo Clinic

Clinical Genetics | September 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/cge.70246 | PMID 42713681 Get It

ABSTRACT The cohesin complex, composed of SMC1, SMC3, RAD21, and STAG1/STAG2, is essential for chromosome cohesion, DNA repair, and transcriptional regulation. Pathogenic variants in cohesin components cause cohesinopathies. The classical characteristics of cohesinopathies include developmental delay (DD), intellectual disability (ID), feeding difficulties, hypotonia, short stature, hearing loss, and dysmorphic features. Here, we present a 5‐year‐old boy with classical cohesinopathy features, including DD/ID and feeding difficulties, along with non‐classical features such as hypoglycemia, recurrent fever, and immunodeficiency. Trio exome sequencing identified a novel de novo missense variant of uncertain significance (NM_005862.3:c.643G>A(p.Val215Ile)) in the STAG1 gene. The variant localizes to the RAD21 interaction interface, and molecular dynamics (MD) simulations revealed conformational changes comparable to other STAG1 variants reported as likely pathogenic in patients, supporting a deleterious effect which may disrupt the STAG1‐RAD21 interaction interface. This case expands the phenotypic and molecular spectrum of STAG1‐related cohesinopathy and advances our understanding of the disease mechanism.
Cognition and Heart Failure Subtypes: A Large Health Care System Real‐World Cohort
Satyadev, Nihal , Lasiichuk, Iryna, Shourav, Md Manjurul Islam , Vallamchetla, Saikrishna , McGrath, Caitlin, Monsanto, Michael Acevedo , Adedinsewo, Demilade , Meschia, James F. , Lin, Michelle , Lin, Michelle P , Meschia, James F , Adedinsewo, Demilade A , Shourav, Md Manjurul Islam , Vallamchetla, Sai Krishna

Mayo Clinic

Journal of the American Heart Association | September 9, 2026 | Volume: 15 | Issue: 18 | Pages: No page available

10.1161/jaha.126.051559 | PMID 42714589 Get It

Background Studies suggest that hypoperfusion from heart failure (HF) may contribute to cognitive decline. However, the relationship between the HF subtypes and cognition remains poorly described in real‐world populations. Methods We conducted a cross‐sectional study of patients aged ≥18 years seen at the Mayo Clinic in 2022 who underwent echocardiogram and cognitive assessment within 1 year. HF was classified per the 2022 American Heart Association as no HF, HF with preserved ejection fraction (EF), HF with mildly reduced EF, and HF with reduced EF. Cognitive impairment was categorized using the Montreal Cognitive Assessment score as normal (≥26), mild (18–25), and moderate to severe (<18). Linear regression assessed EF–Montreal Cognitive Assessment correlation and logistic regression the association between HF subtypes and cognitive dysfunction, adjusting for age, sex, race, and vascular risk factors. Results A total of 1592 patients met inclusion criteria (mean age, 75.7±13.8 years; 48.5% women). Lower EF was associated with worse cognitive performance (postadjustment β=0.033, P =0.013). Patients with HF with reduced EF and patients with HF with preserved EF had significantly lower Montreal Cognitive Assessment scores than those without HF (17.6±6.2 and 18.9±5.8 versus 19.9±6.0, P <0.001). The prevalence of moderate to severe cognitive impairment was highest in HF with reduced EF (43.3%), followed by HF with preserved EF (34.4%), no heart failure (28.6%), and HF with mildly reduced EF (23.4%) (adjusted trend P =0.032). Conclusions HF, independent of ejection fraction alone, is associated with cognitive impairment. Further studies should confirm these findings and evaluate the impact of interventions targeting EF and HF subtypes on cognitive outcomes.
Building trauma-informed physical therapists: a mixed-methods evaluation of a multimodal training module in hybrid DPT education
Parr, Rebecca E. , Richardson, Michael V., Anderson, Kristen, Anderson, Kristen

Mayo Clinic

Physiotherapy Theory and Practice | September 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-16

10.1080/09593985.2026.2730589 | PMID 42708499 Get It

Electrochemical immunosensor-enabled liquid biopsy of extracellular vesicles for diagnosis of metabolic dysfunction-associated steatohepatitis
Nguyen, Thi Thanh Qui, Lee, Seonhwa , Mauer, Amy S. , Giron, Anthony, Cedillo‐Alcantar, Diana F. , Graham, Rondell, Allen, Alina, Revzin, Alexander, Choi, Daheui , Hoyos‐Vega, José M. de , Daniel, P. Vineeth , Eller, Michael J. , Stybayeva, Gulnaz , Lazaridis, Konstantinos , Malhi, Harmeet , Revzin, Alexander

Mayo Clinic

No container title available | September 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.02.26362088 | PMID 42818423 Get It

Abstract Accurate, noninvasive biomarkers for diagnosis and longitudinal monitoring of metabolic dysfunction–associated steatohepatitis (MASH) remain an urgent unmet clinical need. Here, we describe an electrochemical immunoassay that involves capturing hepatic extracellular vesicles (EVs) on antibody-modified electrodes followed by detecting EV-borne biomarkers using redox active gold nanoparticles (AuNPs). The intensity of electrochemical redox signal represents a quantitative measure of biomarker abundance. Three MASH-associated biomarkers—S100A11, TNF-α, and TGF-β1—were analyzed on hepatic EVs to assess steatotic, inflammatory, and fibrotic states of the diseased liver. The electrochemical signals for individual biomarkers were added into a composite EV MASH score. Plasma samples from 28 patients with MASH, 22 healthy controls, and 27 patients with non-MASH liver disease were scored in this manner, revealing 100% accuracy in the training cohort and >90% accuracy in an independent validation cohort. Our electrochemical immunosensor represents a minimally invasive liquid liver biopsy, offering a promising alternative to solid liver biopsies for screening and monitoring of MASH. One Sentence Summary Circulating hepatic extracellular vesicles carry biomarkers of liver injury enabling accurate, minimally invasive MASH diagnosis in blood.
Cognitive impairment as a manifestation of SPG7: case report
Guido, Fiorella S., Gavrilova, Ralitza H. , Tobin, W. Oliver , Basso, Michael R. , Tobin, W Oliver , Guido, Fiorella

Mayo Clinic

Neurocase | September 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-7

10.1080/13554794.2026.2729249 | PMID 42702075 Get It

Comparative Dosing of Bevacizumab for Radiation Necrosis: Impact of Tumor Type on Edema Response
Schultz, Sydney E., Labib, Milisia, Breit, Jeff, Barreto, Jasón, Mead‐Harvey, Carolyn , Behairy, Mohamad, Nurioglu, Aylin, White, Jessica, Valerius, Allison , Taraba, Jodi L. , Soefje, Scott, Hoefs, Gena, Caron, Samantha, Ruff, Deborah, Uhm, Joon, Lachance, Daniel, Kizilbash, Dr Sani, Campian, Jian, Geyer, Susan, Neth, Bryan, Sener, Ugur, Schultz, Sydney , Barreto, Jason N. , Behair, Mohamad, White, Jessica B. , Karbhari, Nishika , Taraba, Jodi L , Soefje, Scott A. , Hoefs, Gena E, Caron, Samantha, Ruff, Michael W. , Uhm, Joon H. , Lachance, Daniel Honore , Kizilbash, Sani H. , Campian, Jian , Geyer, Susan M. , Neth, Bryan J. , Sener, Uğur

Mayo Clinic

No container title available | September 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10795946/v1 Get It

Abstract Purpose Bevacizumab is an effective treatment for radiation necrosis; dose dependent radiographic and edema response data are lacking. Methods Multicenter, retrospective cohort study of adult patients with primary central nervous system tumors or brain metastases who received bevacizumab for radiation necrosis between June 2021 and July 2024. Patients were grouped by bevacizumab dose (7.5 mg/kg vs 10 mg/kg administered every three weeks). Primary outcome was edema response, assessed by a blinded neuro-oncologist. Secondary outcomes included contrast enhancing disease response, clinical response, adverse events, treatment discontinuation, and re-dosing for recurrent radiation necrosis. Analyses were performed with and without adjustment for tumor type. Results 104 patients were included (7.5 mg/kg, n = 53; 10 mg/kg, n = 51). Edema response differed between dosing groups in unadjusted analyses (p = 0.032), favoring the 7.5 mg/kg cohort; however, this association was attenuated after adjustment for tumor type. Contrast enhancing disease response did not differ between groups in either unadjusted or adjusted analyses (p = 0.43). Clinical response was higher in the 7.5 mg/kg group (65.2% vs 37.8%, p = 0.013). Tumor type differed significantly between cohorts (p < 0.001), with more primary CNS tumors in the 10 mg/kg group. Rates of adverse events, treatment discontinuation, and re-dosing were similar. Conclusions While lower-dose bevacizumab was associated with greater edema reduction in unadjusted analyses, this effect was attenuated after accounting for tumor type. Importantly, 7.5 mg/kg dosing appeared sufficient for achieving edema control and contrast enhancing disease response. These findings support an individualized approach to bevacizumab dosing in radiation necrosis and highlight the need for prospective, tumor-stratified studies.